Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Inhibition of glycogen synthase kinase-3 activity leads to epigenetic silencing of nuclear factor κB target genes and induction of apoptosis in chronic lymphocytic leukemia B cells

Andrei V. Ougolkov, Nancy D. Bone, Martin E. Fernandez-Zapico, Neil E. Kay, Daniel D. Billadeau

Blood (2007) 110 (2): 735–742.

https://doi.org/10.1182/blood-2006-12-060947

Published: 2007

Journal Articles

Alemtuzumab and Rituximab for Therapy of Patents with Early Stage High Risk CLL: Report of a Planned Interim Analysis.

Clive S. Zent, MD, Nancy D. Bone, Timothy G. Call, MD, Tait D. Shanafelt, MD, Susan M. Geyer, PhD, Charla R. Secreto, Diane F. Jelinek, PhD, Gordon W. Dewald, PhD, Neil E. Kay, MD

Blood (2006) 108 (11): 2829.

https://doi.org/10.1182/blood.V108.11.2829.2829

Published: 2006

Journal Articles

Expression of Tcl-1 as a Potential Prognostic Factor for Treatment Outcome in B-Cell Chronic Lymphocytic Leukemia.

Rebekah E. Browning, BA, David M. Lucas, PhD, Susan M. Geyer, PhD, Diane F. Jelinek, PhD, Renee C. Tschumper, Timothy G. Call, MD, Tait D. Shanafelt, MD, Clive S. Zent, MD, Nancy D. Bone, Gordon W. Dewald, PhD, Thomas S. Lin, MD, Nyla A. Heerema, PhD, Michael R. Grever, MD, Neil E. Kay, MD, John C. Byrd, MD

Blood (2006) 108 (11): 2792.

https://doi.org/10.1182/blood.V108.11.2792.2792

Published: 2006

Journal Articles

Prognostic Importance of CD49d Expression in Chronic Lymphocytic Leukemia.

Tait D. Shanafelt, MD, Nancy D. Bone, Susan M. Geyer, PhD, Betsy LaPlant, Thomas E. Witzig, MD, Susan Schwager, Gordon W. Dewald, PhD, Greg S. Nowakowski, MD, Renee C. Tschumper, MD, Clive S. Zent, MD, Timothy G. Call, MD, Diane F. Jelinek, PhD, Neil E. Kay, MD

Blood (2006) 108 (11): 2776.

https://doi.org/10.1182/blood.V108.11.2776.2776

Published: 2006

Journal Articles

Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia

Neil E. Kay, Susan M. Geyer, Timothy G. Call, Tait D. Shanafelt, Clive S. Zent, Diane F. Jelinek, Renee Tschumper, Nancy D. Bone, Gordon W. Dewald, Thomas S. Lin, Nyla A. Heerema, Lisa Smith, Michael R. Grever, John C. Byrd

Blood (2006) 109 (2): 405–411.

https://doi.org/10.1182/blood-2006-07-033274

Published: 2006

Journal Articles

Targeting Vla-4 Reduces Cell Adhesion Mediated Drug Resistance in Chronic Lymphocytic Leukemia: Rationale for Anti Vla-4 Therapy.

Grzegorz S. Nowakowski, MD, Thomas E. Witzig, MD, Nancy D. Bone, Yean K. Lee, Tait D. Shanafelt, MD, Neil E. Kay, MD

Blood (2005) 106 (11): 1182.

https://doi.org/10.1182/blood.V106.11.1182.1182

Published: 2005

Journal Articles

Hypoxia Inducible Factor-1α Is over Expressed in CLL B Cells Because of an Impaired Proteasome Pathway Associated with Defective Interaction with von Hippel-Landau Protein.

Yean K. Lee, Ann K. Strege, Nancy D. Bone, Linda E. Wellik, D. A. Chan, A. J. Giaccia, Debabrata Mukhopadhyay, MD, PhD, Neil E. Kay, MD

Blood (2005) 106 (11): 2115.

https://doi.org/10.1182/blood.V106.11.2115.2115

Published: 2005

Journal Articles

Tumor Cells Resistant to Alemtuzumab Complement Mediated Cytotoxicity in Patients with High Risk Previously Untreated Early Stage CLL: A Possible Mechanism of Treatment Failure.

Clive S. Zent, MD, Nancy D. Bone, Susan M. Geyer, PhD, Neil E. Kay, MD

Blood (2005) 106 (11): 2973.

https://doi.org/10.1182/blood.V106.11.2973.2973

Published: 2005

Journal Articles

Proteomic Analysis of Chronic Lymphocytic Leukemia Cells Identifies Vimentin as a Novel Prognostic Factor for Aggressive Disease.

Grzegorz S. Nowakowski, MD, Yean K. Lee, Nancy D. Bone, William G. Morice, MD, David Barnidge, PhD, Diane F. Jelinek, PhD, Renee Tschumper, Tait D. Shanafelt, MD, Clive S. Zent, MD, Laura Z. Rassenti, PhD, Thomas J. Kipps, MD, Neil E. Kay, MD

Blood (2005) 106 (11): 707.

https://doi.org/10.1182/blood.V106.11.707.707

Published: 2005

Journal Articles

Adaphostin-induced apoptosis in CLL B cells is associated with induction of oxidative stress and exhibits synergy with fludarabine

Tait D. Shanafelt, Yean K. Lee, Nancy D. Bone, Ann K. Strege, Ven L. Narayanan, Edward A. Sausville, Susan M. Geyer, Scott H. Kaufmann, Neil E. Kay

Blood (2005) 105 (5): 2099–2106.

https://doi.org/10.1182/blood-2004-06-2205

Published: 2005

Journal Articles

CLL B Cell Interaction with Bone Biopsy Generated Marrow Stromal Elements Enhances Their Apoptosis Resistance in Association with an Angiogenic Switch.

Neil E. Kay, MD, Ann K. Strege, BS, Tait D. Shanafelt, MD, Nancy D. Bone, BS, Yean K. Lee, BS

Blood (2004) 104 (11): 1914.

https://doi.org/10.1182/blood.V104.11.1914.1914

Published: 2004

Journal Articles

Motexafin Gadolinium, a Redox Mediator, Induces Apoptosis in Chronic Lymphocytic Leukemia B Cells and Is Additive or Synergistic with Fludarabine.

Louie Naumovski, MD-PhD, Nancy D. Bone, BA, Mint Sirisawad, BA, Richard Miller, MD, Diane F. Jelinek, PhD, Renee C. Tschumper, BA, Neil E. Kay, MD

Blood (2004) 104 (11): 4799.

https://doi.org/10.1182/blood.V104.11.4799.4799

Published: 2004

Journal Articles

Adaphostin-Induced Apoptosis in CLL B-Cells Is Associated with Induction of Oxidative Stress and Exhibits Synergy with Fludarabine.

Tait D. Shanafelt, M.D., Y. Kit Lee, Nancy D. Bone, Ann K. Strege, Scott H. Kaufmann, M.D., Ph.D., Neil E. Kay, M.D.

Blood (2004) 104 (11): 3482.

https://doi.org/10.1182/blood.V104.11.3482.3482

Published: 2004

Journal Articles

Combination Chemotherapy with Pentostatin, Cyclophosphamide and Rituximab Induces High Rate of Remissions Including Complete Responses and Achievement of Minimal Residual Disease in Previously Untreated B-Chronic Lymphocytic Leukemia.

Neil E. Kay, MD, Susan M. Geyer, PhD, Thomas Lin, MD, Timothy G. Call, MD, Diane F. Jelinek, PhD, Nancy D. Bone, MS, Gordon W. Dewald, PhD, Nyla L. Heerema, PhD, Renee Tschumper, BS, L. Smith, Michael R. Grever, MD, John C. Byrd, MD

Blood (2004) 104 (11): 339.

https://doi.org/10.1182/blood.V104.11.339.339

Published: 2004

Journal Articles

VEGF receptor phosphorylation status and apoptosis is modulated by a green tea component, epigallocatechin-3-gallate (EGCG), in B-cell chronic lymphocytic leukemia

Yean K. Lee, Nancy D. Bone, Ann K. Strege, Tait D. Shanafelt, Diane F. Jelinek, Neil E. Kay

Blood (2004) 104 (3): 788–794.

https://doi.org/10.1182/blood-2003-08-2763

Published: 2004

NARROW

Inhibition of glycogen synthase kinase-3 activity leads to epigenetic silencing of nuclear factor κB target genes and induction of apoptosis in chronic lymphocytic leukemia B cells

Alemtuzumab and Rituximab for Therapy of Patents with Early Stage High Risk CLL: Report of a Planned Interim Analysis.

Expression of Tcl-1 as a Potential Prognostic Factor for Treatment Outcome in B-Cell Chronic Lymphocytic Leukemia.

Prognostic Importance of CD49d Expression in Chronic Lymphocytic Leukemia.

Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia

Targeting Vla-4 Reduces Cell Adhesion Mediated Drug Resistance in Chronic Lymphocytic Leukemia: Rationale for Anti Vla-4 Therapy.

Hypoxia Inducible Factor-1α Is over Expressed in CLL B Cells Because of an Impaired Proteasome Pathway Associated with Defective Interaction with von Hippel-Landau Protein.

Tumor Cells Resistant to Alemtuzumab Complement Mediated Cytotoxicity in Patients with High Risk Previously Untreated Early Stage CLL: A Possible Mechanism of Treatment Failure.

Proteomic Analysis of Chronic Lymphocytic Leukemia Cells Identifies Vimentin as a Novel Prognostic Factor for Aggressive Disease.

Adaphostin-induced apoptosis in CLL B cells is associated with induction of oxidative stress and exhibits synergy with fludarabine

CLL B Cell Interaction with Bone Biopsy Generated Marrow Stromal Elements Enhances Their Apoptosis Resistance in Association with an Angiogenic Switch.

Motexafin Gadolinium, a Redox Mediator, Induces Apoptosis in Chronic Lymphocytic Leukemia B Cells and Is Additive or Synergistic with Fludarabine.

Adaphostin-Induced Apoptosis in CLL B-Cells Is Associated with Induction of Oxidative Stress and Exhibits Synergy with Fludarabine.

Combination Chemotherapy with Pentostatin, Cyclophosphamide and Rituximab Induces High Rate of Remissions Including Complete Responses and Achievement of Minimal Residual Disease in Previously Untreated B-Chronic Lymphocytic Leukemia.

VEGF receptor phosphorylation status and apoptosis is modulated by a green tea component, epigallocatechin-3-gallate (EGCG), in B-cell chronic lymphocytic leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only